Form 4 for DERM Journey Medical Corp
Accepted 2023-12-08 00:00:00 ET · period of report 2023-11-07 · accession 0001104659-23-124743 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-12-08 | 2023-11-07+ | DERM | Paley Jeffrey | Dir | S - Sale | $3.51 | -2,500 | 114.2K | -2% | -$8,771 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.0001 per share | 2023-11-07 | S | D | 2,245 | $3.48 | 114,472 | D | — | — | (F1) The reporting person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of sales of the Issuer's common stock reported herein, as well as the sales reported on a Form 4 filed November 29, 2023, being matched against non-exempt purchases of 4,245 shares of common stock made on September 21, 2023. Accordingly, the reporting person has paid to the Issuer (i) $1,724.98 in connection with the matched sales reported herein and (ii) $4,189.95 in connection with the matched sales made on November 28, 2023, representing the aggregate short-swing profit realized by the reporting person, less transaction costs. Includes 10,000 restricted units of which will vest in full on July 1, 2024 and 27,472 restricted stock units of which will vest on July 21, 2024. |
| 2 | Common | Common Stock, par value $0.0001 per share | 2023-11-08 | S | D | 255 | $3.76 | 114,217 | D | — | — | (F1) The reporting person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of sales of the Issuer's common stock reported herein, as well as the sales reported on a Form 4 filed November 29, 2023, being matched against non-exempt purchases of 4,245 shares of common stock made on September 21, 2023. Accordingly, the reporting person has paid to the Issuer (i) $1,724.98 in connection with the matched sales reported herein and (ii) $4,189.95 in connection with the matched sales made on November 28, 2023, representing the aggregate short-swing profit realized by the reporting person, less transaction costs. Includes 10,000 restricted units of which will vest in full on July 1, 2024 and 27,472 restricted stock units of which will vest on July 21, 2024. |